Biohaven (BHVN)

• Market cap: $1.56B
• 1 day: 8.97%
• 5 days: 4.33%
• 1 month: -8.18%
• 3 months: 0.96%
• 6 months: -50.44%
• Year to date: -60.57%
• 1 year: -62.31%
• 5 years: 105.88%
• 10 years: 105.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

178% more call options, than puts

Call options by funds: $54.1M | Put options by funds: $19.4M

42% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 69

2.68% less ownership

Funds ownership: 87.87% [Q1] → 85.19% (-2.68%) [Q2]

6% less funds holding

Funds holding: 263 [Q1] → 247 (-16) [Q2]

27% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 52

43% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 4 (-3) [Q2]

44% less capital invested

Capital invested by funds: $2.2B [Q1] → $1.23B (-$974M) [Q2]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $26
• Avg. target: $48
• High target: $75

10 analyst ratings

• positive: 10 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Samantha Semenkow	$28	Buy Initiated	17 Sep 2025
UBS Ashwani Verma	$26	Buy Maintained	16 Sep 2025
Raymond James Chris Raymond	$75	Strong Buy Initiated	3 Sep 2025
BTIG Thomas Shrader	$60	Buy Maintained	19 Aug 2025
Leerink Partners Marc Goodman	$50	Outperform Maintained	12 Aug 2025